04:25 PM EST, 11/26/2024 (MT Newswires) -- InnoCan Pharma ( INNPF ) after close Tuesday reported positive results from a basic safety assessment study evaluating its LPT-CBD administered as a single injection in Gottingen minipigs.

The drug was administered in three ascending doses, and the animals were closely monitored over a 28-day period for key safety parameters. These included clinical observations, vital signs, blood parameters, and local injection site reactions. Encouragingly, no adverse events were recorded during the study.

LPT-CBD is an injectable liposomal formulation designed for the sustained release of CBD, targeting the treatment of chronic pain. Previous preclinical studies in various animal models have demonstrated prolonged CBD pharmacokinetics, delivering long-term efficacy.

"We are thrilled that LPT-CBD once again demonstrates a promising safety profile, particularly in minipigs, which are widely regarded as a strong toxicology model," said Chief Scientific Officer Prof. Chezy Barenholz.